Contact this trialFirst, we need to learn more about you.
Alkylating agents
Enfortumab Vedotin + Pembrolizumab for Bladder Cancer
Recruiting2 awardsPhase 3
Stanford, California
This trial is testing a new combination of drugs to treat bladder cancer that has spread to the lymph nodes. The new combination is enfortumab vedotin plus pembrolizumab, which will be given before surgery. The trial will compare this new combination to the standard of care, which is neoadjuvant chemotherapy with gemcitabine and cisplatin, followed by surgery. The trial will measure how well the new combination works by looking at the pathologic complete response rate and event free survival.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service